Quality of life in Palestinian patients with end-stage renal disease receiving treatment by haemodialysis: a cross-sectional study

• Published in: The Lancet (British edition) 2018-02, Vol.391, p.S32-S32
• Main Authors: Zyoud, Sa'ed H, Daraghmeh, Dala N, Mezyed, Diana O, Khdeir, Razan L, Sawafta, Mayas N, Ayaseh, Nora A, Tabeeb, Ghada H, Sweileh, Waleed M, Awang, Rahmat, Al-Jabi, Samah W
• Format: Article
• Language: English
• Subjects: Cross-sectional studies; Data collection; End-stage renal disease; Hemodialysis; Kidney diseases; Quality of life; Statistical analysis
• ISSN: 0140-6736; 1474-547X
• DOI: 10.1016/S0140-6736(18)30357-X

Haemodialysis is a life-saving but burdensome therapy for patients with end-stage renal disease, which can substantially impair health-related quality of life (HRQOL) and outcomes. The aim of this study was to determine the patterns of HRQOL and to identify the risk factors for reduced HRQOL in Palestinian patients receiving treatment by haemodialysis. This cross-sectional study was done between June 15, 2014, and Jan 15, 2015, using the EuroQOL-5 Dimensions instrument (EQ-5D-5L) for the assessment of HRQOL. We approached patients with end-stage renal disease undergoing haemodialysis at inpatient hospitals from ten different settings at a national level. The study protocol was approved by the Ethics Committee of An-Najah National University. Informed verbal consent was obtained from each participant before the start of the interview. Multiple linear regression was used to estimate which variables were significantly associated with reduced HRQOL. 267 (96%) of 277 eligible patients consented to participate. 139 (52%) participants were men, and the mean age was 53·3 years (SD 16·2). 177 (66%) patients had been treated by haemodialysis for less than 4 years. The reported HRQOL, as measured by mean EQ-5D-5L index value, was 0·37 (SD 0·44). We found a moderate positive correlation between the EuroQol-visual analogue scales and the EQ-5D-5L index value (r=0·44; p